Novelion Therapeutics (NASDAQ:NVLN) (TSE:QLT) released its quarterly earnings data on Thursday. The biotechnology company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.13), Fidelity Earnings reports. The business had revenue of $40.71 million during the quarter, compared to analysts’ expectations of $40.90 million.
Novelion Therapeutics stock opened at $1.40 on Friday. Novelion Therapeutics has a 52-week low of $0.70 and a 52-week high of $4.80. The firm has a market cap of $23.40 million, a price-to-earnings ratio of -0.21 and a beta of 2.16.
In other Novelion Therapeutics news, major shareholder Healthcare Master Fun Broadfin sold 278,485 shares of the stock in a transaction on Wednesday, December 26th. The stock was sold at an average price of $0.91, for a total transaction of $253,421.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 18.00% of the company’s stock.
NVLN has been the subject of several recent analyst reports. Zacks Investment Research upgraded Novelion Therapeutics from a “hold” rating to a “buy” rating and set a $1.00 price objective for the company in a research note on Tuesday, November 20th. ValuEngine upgraded Novelion Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd.
ILLEGAL ACTIVITY WARNING: “Novelion Therapeutics (NVLN) Announces Quarterly Earnings Results” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/4223187/novelion-therapeutics-nvln-announces-quarterly-earnings-results.html.
About Novelion Therapeutics
Novelion Therapeutics Inc, a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases in the United States, Brazil, and internationally. The company's commercial products include lomitapide hard capsule for the treatment of homozygous familial hypercholesterolemia in adults under the JUXTAPID and LOJUXTA brands; and metreleptin, a recombinant analogue of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPT brand.
Featured Article: 52-Week High/Low Prices For Stock Selection
Receive News & Ratings for Novelion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novelion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.